Compare FCNCN & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
First Citizens BancShares Inc. Depositary Shares each representing a 1/40th interest in a share of 6.625% Non-Cumulative Perpetual Preferred Stock Series E
| Metric | FCNCN | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 1995 | 2024 |
| Metric | FCNCN | YDESW |
|---|---|---|
| Price | $22.45 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 74.7K | 5.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 149.14 | N/A |
| Revenue | ★ $9,541,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.42 | $0.19 |
| 52 Week High | $25.64 | $1.80 |
| Indicator | FCNCN | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 48.06 |
| Support Level | $22.52 | $0.38 |
| Resistance Level | $25.30 | $0.58 |
| Average True Range (ATR) | 0.46 | 0.07 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 69.52 | 38.67 |
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.